A study based on more than 1.5 million percutaneous coronary intervention procedures (such as balloon angioplasty or stent placement to open narrowed coronary arteries) suggests that the use of drug-eluting stents varies widely among U.S. physicians, and is only modestly correlated with the patient's risk of coronary artery restenosis (renarrowing), according to a report published Online First by Archives of Internal Medicine, a JAMA Network publication.
Drug-eluting stents (DES) are effective in reducing restenosis and the benefits are greatest in patients at the highest risk of target-vessel revascularization (TVR). Drug-eluting stents cost more than bare-metal stents (BMS), and they require prolonged dual antiplatelet therapy (DAPT), which increases costs, bleeding and complication risk if DAPT is ended too early, according to the study background.
Amit P. Amin, M.D., M.Sc., of Barnes Jewish Hospital, Washington University School of Medicine, St. Louis, Mo., and colleagues analyzed more than 1.5 million PCI procedures in the National Cardiovascular Data Registry (NCDR) CathPCI registry from 2004 through much of 2010. They sought to examine variation in DES use among physicians, whether predicted TVR risk with bare-metal stents was associated with DES use, and what the estimated clinical and economic consequences were of lower DES use among patients with low TVR risk.
"The present study demonstrates that in current U.S. practice, DES use is prevalent, even among patients at low risk of developing restenosis. There was also significant variation in the rate of DES use by individual physicians. A reduction in DES use among patients at low risk for restenosis was projected to be associated with substantial costs savings with only a small increase in TVR events," the authors note.
According to study results, drug-eluting stent use was 73.9 percent among those at a low risk for TVR, 78 percent among those at moderate risk and 83.2 percent among those at the highest TVR risk.
The study suggests that a 50 percent reduction in the use of DES in low-TVR-risk patients was projected to lower health care costs by about $205 million per year in the U.S., while increasing the overall TVR event rate by 0.5 percent.
"Given the marked variation in physicians' DES use, a strategy of lower DES use among patients at low risk of TVR could present an important opportunity to reduce health care expenditures while preserving the vast majority of their clinical benefit," the authors conclude.
In an invited commentary, Peter W. Groeneveld, M.D., M.S., of the University of Pennsylvania, Philadelphia, writes: "New medical technologies are the primary drivers of rising health care costs, but the U.S. health care system has generally performed poorly in incorporating new drugs, devices, imaging techniques and invasive procedures in a manner that maximizes the value defined as health benefits relative to costs delivered to patients while simultaneously restraining the use of such technologies in settings where they predictably provide little or no value."
"The use pattern of DES during the past nine years illustrates how far away the system is from consistently embracing value-based medical decision making, and it also enumerates the many barriers and inertial practices in U.S. health care that must be surmounted to reach economic sustainability," Groeneveld concludes.
Explore further: Considerably lower risk of stent thrombosis and restenosis in 'new generation' drug-eluting stents
Arch Intern Med. Published online July 9, 2012. doi:10.1001/archinternmed.2012.3093
Arch Intern Med. Published online July 9, 2012. doi:10.1001/archinternmed.2012.2724